Потенциал транс-ресвератрола в коррекции менопаузальных расстройств и возраст-ассоциированных заболеваний
https://doi.org/10.31550/1727-2378-2023-22-5-62-68
Аннотация
Цель обзора: поиск альтернативных путей профилактики возраст-ассоциированной патологии у женщин, обусловленной в том числе прогрессирующим снижением уровня эстрогенов в период менопаузального перехода и постменопаузы.
Основные положения. При наличии противопоказаний к назначению менопаузальной гормональной терапии или на этапе обследования выбор альтернативных способов коррекции климактерических расстройств и системных метаболических нарушений должен соответствовать высокому профилю безопасности и эффективности. В обзоре подробно описаны фармакологические эффекты фитоэстрогена ресвератрола, механизмы реализации эстрогеноподобного, антипролиферативного, противовоспалительного и антиоксидантного
действия и возможности клинического применения в виде пищевых добавок.
Заключение. Назначение фитоэстрогена транс-ресвератрола у женщин в пери- и постменопаузе является альтернативным подходом в снижении выраженности менопаузальных расстройств и профилактики системных метаболических нарушений. Обладая высокой биодоступностью в транс-изомерной форме и высоким профилем безопасности, он является оптимальным негормональным средством коррекции менопаузальных симптомов, торможения некоторых процессов старения, а также имеет значимый потенциал предотвращения возраст-ассоциированных заболеваний, что позволяет существенно улучшить качество жизни женщины в период менопаузы.
Об авторе
П. В. КозловРоссия
Павел Васильевич Козлов, д. м. н., профессор
лечебный факультет; кафедра акушерства и гинекологии
117997; ул. Островитянова, д. 1; Москва
Список литературы
1. Адамян Л.В., Ашрафян Л.А., Андреева Е.Н. и др. Менопауза и климактерическое состояние у женщины . Клинические рекомендации. 2021. 86 c.
2. Koushki M., Amiri-Dashatan N., Ahmadi N. et al. Resveratrol: a miraculous natural compound for diseases treatment. Food Sci. Nutr. 2018;6(8):2473–2490. DOI: 10.1002/fsn3.855
3. Pezzuto J. Resveratrol: Twenty years of growth, development and controversy. Biomol. Ther. 2019;27:1–14. DOI: 10.4062/biomolther.2018.176
4. Sessa M., Balestrieri M.L., Ferrari G. et al. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chem. 2014;147:42–50. DOI: 10.1016/j.foodchem.2013.09.088
5. Chimento A., De Amicis F., Sirianni R. et al. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int. J. Mol. Sci. 2019;20:1381. DOI: 10.3390/ijms20061381
6. Gambini J., Ingles M., Olaso G. et al. Properties of resveratrol: In vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid. Med. Cell. Longev. 2015;2015:837042. DOI: 10.1155/2015/837042
7. Patel K.R., Scott E., Brown V.A. et al. Clinical trials of resveratrol. Ann. N. Y. Acad. Sci. 2011;1215:161–169. DOI: 10.1111/j.1749-6632.2010.05853.x
8. Ruotolo R., Calani L., Fietta E. et al. Antiestrogenic activity of a human resveratrol metabolite. Nutr. Metab. Cardiovasc. Dis. 2013;23(11):1086–1092. DOI: 10.1016/j.numecd.2013.01.002
9. Филиппова О.В. Фитоэстрогены: перспективы применения. Эффективная фармакотерапия. 2020;16(22):30–36.
10. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;14(10):3657–3667. DOI: 10.1210/endo.141.10.7721
11. Leo L., Surico D., Deambrogio F. et al. Preliminary data on the effectiveness of resveratrol in a new formulation in treatment of hot flushes. Minerva Ginecol. 2015;67(5):475–83.
12. Wong R.H., Thaung Zaw J.J., Xian C.J., Howe P.R. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomized, placebo-controlled trial. J. Bone Miner. Res. 2020;35(11):2121–2131. DOI: 10.1002/jbmr.4115
13. Uberti F., Morsanuto V., Aprile S. et al. Biological effects of combined resveratrol and vitamin D3 on ovarian tissue. J. Ovarian Res. 2017;10(1):61. DOI: 10.1186/s13048-017-0357-9
14. Milia R. Improvement of climacteric symptoms with a novel sublingual product containing trans-resveratrol. Progr. Nutr. 2015;17(1):68–72.
15. Сухих Г.Т., Серов В.Н., Адамян Л.В. и др. Алгоритмы ведения пациенток с эндометриозом: согласованная позиция экспертов Российского общества акушеров-гинекологов. Акушерство и гинекология. 2023;(5):159–176. doi: 10.18565/aig.2023.132
16. Kumar N., Goel N. Phenolic acids: Natural versatile molecules with promising therapeutic applications. Biotechnol. Rep. 2019;24:e00370. DOI: 10.1016/j.btre.2019.e00370
17. Desmawati D., Sulastri D. Phytoestrogens and their health effect. Open Access Maced. J. Med. Sci. 2019;7(3):495–499. DOI: 10.3889/oamjms.2019.044
18. Woodward K.A., Draijer R., Thijssen D.H., Low D.A. Polyphenols and microvascular function in humans : a systemic review. Curr. Pharm. Design. 2018;24:203–226. DOI: 10.2174/1381612823666171109103939
19. Zhou Y., Zheng J., Li Y. et al. Natural polyphenols for prevention and treatment of cancer. Nutrients. 2016;8:515. DOI: 10.3390/nu8080515
20. Ferraz da Costa D.C., Pereira Rangel L., Quarti J. et al. Bioactive compounds and metabolites from grapes and red wine in breast cancer chemoprevention and therapy. Molecules 2020;25:3531. DOI: 10.3390/molecules25153531
21. Damianaki A., Bakogeorgou E., Kampa M. et al. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J. Cell Biochem. 2000;78:429–441. DOI: 10.1002/1097-4644(20000901)78:3<429::aid-jcb8>3.0.co;2-m
22. Carter L.G., D’Orazio J.A., Pearson K.J. Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer. 2014;21(3):R209–225. DOI: 10.1530/erc-13-0171
23. Venkatadri R., Muni T., Iyer A.K. et al. Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death. Cell Death Dis. 2016;7:e2104. DOI: 10.1038/cddis.2016.6
24. Chin Y.T., Hsieh M.T., Yang S.H. et al. Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro. Oncotarget. 2014;5(24):12891–12907. DOI: 10.18632/oncotarget.2632
25. Lee-Chang C., Bodogai M., Martin-Montalvo A. et al. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J. Immunol. 2013;191(8):4141–4151. DOI: 10.4049/jimmunol.1300606
26. Jang J.Y., Im E., Kim N.D. Mechanism of resveratrol-induced programmed cell death and new drug discovery against cancer : a review. Int. J. Mol. Sci. 2022;23:13689. DOI: 10.3390/ijms232213689
27. Ma C., Wang Y., Dong L. et al. Anti-inflammatory effect of resveratrol through the suppression of NF-kappa B and JAK/STAT signaling pathways. Acta Biochim. Biophys. Sin. 2015;47:207–213. DOI: 10.1093/abbs/gmu135
28. Donnelly L.E., Newton R., Kennedy G.E. et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol. 2004;287:L774–L783. DOI: 10.1152/ajplung.00110.2004
29. Singh A., Yau Y.F., Leung K.S. et al. Interaction of polyphenols as antioxidant and anti-inflammatory compounds in brain–liver–gut axis. Antioxidants. 2020;9(8):669. DOI: 10.3390/antiox9080669
30. Hou Y., Zhang Y., Mi Y. et al. A novel quinolyl-substituted analogue of resveratrol inhibits lps-induced inflammatory responses in microglial cells by blocking the NF-B/MAPK signaling pathways. Mol. Nutr. Food. Res. 2019;63(20):e1801380. DOI: 10.1002/mnfr.201801380
31. Hu W., Yang E., Ye J. et al. Resveratrol protects neuronal cells from isoflurane-induced inflammation and oxidative stress-associated death by attenuating apoptosis via Akt/p38 MAPK signaling. Exp. Ther. Med. 2018;15:1568–1573. DOI: 10.3892/etm.2017.5527
32. Qi B., Shi C., Meng J. et al. Resveratrol alleviates ethanol-induced neuroinflammation in vivo and in vitro: involvement of TLR2-MyD88-NF-kappa B pathway. Int. J. Biochem. Cell Biol. 2018;103:56–64. DOI: 10.1016/j.biocel.2018.07.007
33. Movahed A., Nabipour I., Lieben Louis X. et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Complement Alternat. Med. 2013;2013:851267. DOI: 10.1155/2013/851267
34. Brasnyó P., Molnár G.A., Mohás M. et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011;106(3):383–389. DOI: 10.1155/2013/851267
35. Liu K., Zhou R., Wang B., Mi M.T. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 2014;99(6):1510–1519. DOI: 10.3945/ajcn.113.082024
36. Zamora-Ros R., Urpi-Sarda M., Lamuela-Raventós R.M. et al. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol. Res. 2012;65(6):615–620. DOI: 10.1016/j.phrs.2012.03.009
37. Magrone T., Magrone M., Russo M.A., Jirillo E. Recent advances on the anti-inflammatory and antioxidant properties of red grape polyphenols: in vitro and in vivo studies. Antioxidants (Basel). 2019;9(1):35. DOI: 10.3390/antiox9010035
38. Xiao K., Ma X.H., Zhong Z. et al. Low-dose trans-resveratrol ameliorates diabetes-induced retinal ganglion cell degeneration via TyrRS/c-Jun pathway. Invest. Ophthalmol. Vis. Sci. 2023;64(7):2. DOI: 10.1167/iovs.64.7.2
39. Guo L., Zhang X., Lv N. et al. Therapeutic role and potential mechanism of resveratrol in atherosclerosis: TLR4/NF-κB/HIF-1α. Mediators Inflamm. 2023;2023:1097706. DOI: 10.1155/2023/1097706
40. Singh A., Yau Y.F., Leung K.S. et al. Interaction of polyphenols as antioxidant and anti-inflammatory compounds in brain–liver–gut axis. Antioxidants (Basel). 2020;9(8):669. DOI: 10.3390/antiox9080669
41. Liu L.L., He J.H., Xie H.B. et al. Resveratrol induces antioxidant and heat shock protein mRNA expression in response to heat stress in black-boned chickens. Poult. Sci. 2014;93(1):54–62. DOI: 10.3382/ps.2013-03423
42. Lastra C.A., Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Mol. Nutr. Food Res. 2005;49(5):405–430. DOI: 10.1002/mnfr.200500022
43. Kohandel Z., Darrudi M., Naseri K. et al. The role of resveratrol in aging and senescence: a focus on molecular mechanisms. Curr. Mol. Med. 2023. DOI: 10.2174/1566524023666230602162949
44. Qu L., Yu Y., Qiu L. et al. Sirtuin 1 regulates matrix metalloproteinase-13 expression induced by Porphyromonas endodontalis lipopolysaccharide via targeting nuclear factor-KB in osteoblasts. J. Oral Microbiol. 2017;9(1):1317578. DOI: 10.1080/20002297.2017.1317578
45. Kala R., Shah H.N., Martin S.L., Tollefsbol T.O. Epigenetic-based combinatorial resveratrol and ptero-stilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent gamma-H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer. 2015;15:672. DOI: 10.1186/s12885-015-1693-z
46. Leite Santos C., K Vizuete A.F., Becker Weber F. et al. Age-dependent effects of resveratrol in hypothalamic astrocyte cultures. Neuroreport. 2023;34(8):419–425. DOI: 10.1097/WNR.0000000000001906
47. Safer J.D. Thyroid hormone action on skin. Dermato-Endocrinology. 2011;3:211–215. DOI: 10.4161/derm.17027
48. Chen Y., Luga J. Brain-skin connection: stress, inflammation and skin health. Inflamm. Allergy Drug Targets. 2014;13:177–190. DOI: 10.2174/1871528113666140522104422
49. Lephart E.D., Naftolin F. Menopause and the skin: old favorites and new innovations in cosmeceuticals for estrogen-deficient skin. Dermatol. Ther. 2021;11:53–69. DOI: 10.1007/s13555-020-00468-7
50. Qasem R.J. The estrogenic activity of resveratrol : a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit. Rev. Toxicol. 2020;5:439–462. DOI: 10.1080/10408444.2020.1762538
51. Lephart E.D. Equol’s efficacy is greater than astaxanthin for antioxidants, extracellular matrix integrity & breakdown, growth factors and inflammatory biomarkers via human skin gene expression analysis. J. Funct. Foods. 2019;59:380–393.
52. Chedea V.S., Vicas S.I., Sticozzi C. et al. Resveratrol: from diet to topical usage. Food Funct. 2017;8:3879–3892. DOI: 10.1039/C7FO01086A
53. Ratz-Lyko A., Arct J. Resveratrol as an active ingredient for cosmetic and dermatological applications : a review. J. Cosmet. Laser Ther. 2019;21:84–90. DOI: 10.1080/14764172.2018.1469767
54. Gugleva V., Zasheva S., Hristova M., Andonova V. Topical use of resveratrol: Technological aspects. Pharmacia. 2020;67:89–94. DOI: 10.3897/pharmacia.67.e48472
55. Hausenblas H. Effects of resveratrol and collagen supplementation on facial aging. Nat. Med. J. 2014;5:1–8.
56. Brinke A.S., Janssens-Bocker C., Kerscher M. Skin anti-aging benefits of a 2 % resveratrol emulsion. J. Cosmet. Dermatol. Sci. Appl. 2021;11:155–168.
57. Martinez J., Moreno J.J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 2000;59(7):865–870. DOI: 10.1016/s0006-2952(99)00380-9
58. Thaung Zaw J.J., Howe P.R., Wong R.H. Long-term effects of resveratrol on cognition, cerebrovascular function and cardiometabolic markers in postmenopausal women: a 24-month randomised, double-blind, placebo-controlled, crossover study. Clin. Nutr. 2021;40(3):820–829. DOI: 10.1016/j.clnu.2020.08.025
Рецензия
Для цитирования:
Козлов П.В. Потенциал транс-ресвератрола в коррекции менопаузальных расстройств и возраст-ассоциированных заболеваний. Доктор.Ру. 2023;22(5):62-68. https://doi.org/10.31550/1727-2378-2023-22-5-62-68
For citation:
Kozlov P.V. Potential of Trans-Resveratrol in the Prevention of Menopausal Disorders and Age-Associated Morbidity. Title. 2023;22(5):62-68. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-5-62-68